Cargando…

Anti-ST2 Nanoparticle Alleviates Lung Inflammation by Targeting ILC2s-CD4(+)T Response

BACKGROUND: Asthma has been regarded as an inflammatory disease, and group 2 innate lymphoid cells (ILC2s) are implicated in asthma pathogenesis. However, no strategy is available to block ILC2s function. Efficiency is also limited due to the use of systemic or subcutaneous routes of administration....

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yumin, Shi, Weifeng, Wang, Honghai, Yue, Jiawei, Mao, Yijie, Zhou, Wei, Kong, Xinagmin, Guo, Qiqiong, Zhang, Lirong, Xu, Pengxiao, Wang, Yuyue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7721292/
https://www.ncbi.nlm.nih.gov/pubmed/33299314
http://dx.doi.org/10.2147/IJN.S268282
_version_ 1783620008973172736
author Wu, Yumin
Shi, Weifeng
Wang, Honghai
Yue, Jiawei
Mao, Yijie
Zhou, Wei
Kong, Xinagmin
Guo, Qiqiong
Zhang, Lirong
Xu, Pengxiao
Wang, Yuyue
author_facet Wu, Yumin
Shi, Weifeng
Wang, Honghai
Yue, Jiawei
Mao, Yijie
Zhou, Wei
Kong, Xinagmin
Guo, Qiqiong
Zhang, Lirong
Xu, Pengxiao
Wang, Yuyue
author_sort Wu, Yumin
collection PubMed
description BACKGROUND: Asthma has been regarded as an inflammatory disease, and group 2 innate lymphoid cells (ILC2s) are implicated in asthma pathogenesis. However, no strategy is available to block ILC2s function. Efficiency is also limited due to the use of systemic or subcutaneous routes of administration. The purpose of this study was to investigate the effects of nanoparticles targeting suppression of tumorigenicity 2 (ST2), which is the ILC2 receptor, to alleviate lung inflammation in the murine model of asthma. METHODS: The ultra-small SPIO nanoparticles were firstly synthesized, OVA-induced mice were administered by anti-ST2-conjugated nanoparticles. The inflammatory degree of the lung was investigated by H&E. The percentages of ILC2s and CD4(+)T cells in bronchoalveolar lavage fluid (BALF) and lung tissue were determined by FACS. Th2-cytokine and OVA-IgE levels were detected by real-time PCR and ELISA, respectively. RESULTS: Treatment with anti-ST2-conjugated nanoparticles significantly alleviated airway inflammation, IL-33 and IL-13 levels and the percentage of CD4(+)T cells. The percentage of ILC2s was increased, whereas the levels of IL-13 and IL-5 expressed by ILC2s were reduced. CONCLUSION: In the present study, we demonstrated that anti-ST2-conjugated nanoparticles can efficiently control lung inflammation in OVA-induced mice by reducing the ability of ILC2s to produce IL-5 and IL-13, thereby reducing CD4+T cells. Our study also demonstrated that the nanoparticle delivery system could improve the performance of anti-ST2, which may be used as a strategic tool to expand the current drug market.
format Online
Article
Text
id pubmed-7721292
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-77212922020-12-08 Anti-ST2 Nanoparticle Alleviates Lung Inflammation by Targeting ILC2s-CD4(+)T Response Wu, Yumin Shi, Weifeng Wang, Honghai Yue, Jiawei Mao, Yijie Zhou, Wei Kong, Xinagmin Guo, Qiqiong Zhang, Lirong Xu, Pengxiao Wang, Yuyue Int J Nanomedicine Original Research BACKGROUND: Asthma has been regarded as an inflammatory disease, and group 2 innate lymphoid cells (ILC2s) are implicated in asthma pathogenesis. However, no strategy is available to block ILC2s function. Efficiency is also limited due to the use of systemic or subcutaneous routes of administration. The purpose of this study was to investigate the effects of nanoparticles targeting suppression of tumorigenicity 2 (ST2), which is the ILC2 receptor, to alleviate lung inflammation in the murine model of asthma. METHODS: The ultra-small SPIO nanoparticles were firstly synthesized, OVA-induced mice were administered by anti-ST2-conjugated nanoparticles. The inflammatory degree of the lung was investigated by H&E. The percentages of ILC2s and CD4(+)T cells in bronchoalveolar lavage fluid (BALF) and lung tissue were determined by FACS. Th2-cytokine and OVA-IgE levels were detected by real-time PCR and ELISA, respectively. RESULTS: Treatment with anti-ST2-conjugated nanoparticles significantly alleviated airway inflammation, IL-33 and IL-13 levels and the percentage of CD4(+)T cells. The percentage of ILC2s was increased, whereas the levels of IL-13 and IL-5 expressed by ILC2s were reduced. CONCLUSION: In the present study, we demonstrated that anti-ST2-conjugated nanoparticles can efficiently control lung inflammation in OVA-induced mice by reducing the ability of ILC2s to produce IL-5 and IL-13, thereby reducing CD4+T cells. Our study also demonstrated that the nanoparticle delivery system could improve the performance of anti-ST2, which may be used as a strategic tool to expand the current drug market. Dove 2020-12-03 /pmc/articles/PMC7721292/ /pubmed/33299314 http://dx.doi.org/10.2147/IJN.S268282 Text en © 2020 Wu et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Wu, Yumin
Shi, Weifeng
Wang, Honghai
Yue, Jiawei
Mao, Yijie
Zhou, Wei
Kong, Xinagmin
Guo, Qiqiong
Zhang, Lirong
Xu, Pengxiao
Wang, Yuyue
Anti-ST2 Nanoparticle Alleviates Lung Inflammation by Targeting ILC2s-CD4(+)T Response
title Anti-ST2 Nanoparticle Alleviates Lung Inflammation by Targeting ILC2s-CD4(+)T Response
title_full Anti-ST2 Nanoparticle Alleviates Lung Inflammation by Targeting ILC2s-CD4(+)T Response
title_fullStr Anti-ST2 Nanoparticle Alleviates Lung Inflammation by Targeting ILC2s-CD4(+)T Response
title_full_unstemmed Anti-ST2 Nanoparticle Alleviates Lung Inflammation by Targeting ILC2s-CD4(+)T Response
title_short Anti-ST2 Nanoparticle Alleviates Lung Inflammation by Targeting ILC2s-CD4(+)T Response
title_sort anti-st2 nanoparticle alleviates lung inflammation by targeting ilc2s-cd4(+)t response
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7721292/
https://www.ncbi.nlm.nih.gov/pubmed/33299314
http://dx.doi.org/10.2147/IJN.S268282
work_keys_str_mv AT wuyumin antist2nanoparticlealleviateslunginflammationbytargetingilc2scd4tresponse
AT shiweifeng antist2nanoparticlealleviateslunginflammationbytargetingilc2scd4tresponse
AT wanghonghai antist2nanoparticlealleviateslunginflammationbytargetingilc2scd4tresponse
AT yuejiawei antist2nanoparticlealleviateslunginflammationbytargetingilc2scd4tresponse
AT maoyijie antist2nanoparticlealleviateslunginflammationbytargetingilc2scd4tresponse
AT zhouwei antist2nanoparticlealleviateslunginflammationbytargetingilc2scd4tresponse
AT kongxinagmin antist2nanoparticlealleviateslunginflammationbytargetingilc2scd4tresponse
AT guoqiqiong antist2nanoparticlealleviateslunginflammationbytargetingilc2scd4tresponse
AT zhanglirong antist2nanoparticlealleviateslunginflammationbytargetingilc2scd4tresponse
AT xupengxiao antist2nanoparticlealleviateslunginflammationbytargetingilc2scd4tresponse
AT wangyuyue antist2nanoparticlealleviateslunginflammationbytargetingilc2scd4tresponse